Johnson & Johnson’s single-dose vaccine 66% effective

- Advertisement -

Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing Covid-19 in a large trial against multiple variants across three continents.

In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72 per cent in the United States, to 66 per cent in Latin America and just 57 per cent in South Africa, from where a worrying variant has spread.

A high bar has been set by two authorized vaccines from Pfizer/BioNTech and Moderna, which were around 95 per cent effective in preventing symptomatic illness in pivotal trials when given in two doses.

READ  Oman: No side effects reported from COVID-19 vaccine

Those trials, however, were conducted mainly in the United States and before new variants emerged.



- Advertisement -
Khaleej Times

Related Articles

Back to top button